406482-22-2|1-Bromo-2,3-difluoro-4-methoxybenzene| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 406482-22-2 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 406482-22-2 ]

CAS No. :	406482-22-2
Formula :	C₇H₅BrF₂O
M.W :	223.01
SMILES Code :	COC1=C(F)C(F)=C(Br)C=C1
MDL No. :	MFCD07368017
InChI Key :	VZMFIPVRFWZDPI-UHFFFAOYSA-N
Pubchem ID :	21646800

Safety of [ 406482-22-2 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 406482-22-2 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.14
Num. rotatable bonds	1
Num. H-bond acceptors	3.0
Num. H-bond donors	0.0
Molar Refractivity	40.55
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	9.23 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.25
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.79
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.58
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	3.41
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.34
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	3.07

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.32
Solubility	0.107 mg/ml ; 0.000481 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.64
Solubility	0.511 mg/ml ; 0.00229 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.94
Solubility	0.0254 mg/ml ; 0.000114 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.68 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.66

Application In Synthesis of [ 406482-22-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 406482-22-2 ]

[ 406482-22-2 ] Synthesis Path-Downstream 1~35

1
[ 134364-69-5 ]
[ 406482-22-2 ]

Yield	Reaction Conditions	Operation in experiment
	With bromine; triethylamine; In dichloromethane; at 0 - 20℃; for 1.33333h;	Step 2) 2.Og 3-Isobutoxy-4,5,6,6a-tetrahydro-3aH-pentalen-l -one was dissolved in 40 ml DCM. 2.47g Br2 was added drop wise and the mixture was stirred at rt for 20 min. The reaction mixture was cooled to O0C and 3.12 g TEA was slowly added. The cooling bath was removed and the mixture was stirred at rt for 1 h. Filtration and concentration gave a crude product which was purified on silica using 2% MeOH in DCM to produce 2.26 g l-Bromo-2,3-difluoro-4-methoxy-benzene.

References: [1]Patent: WO2009/12954,2009,A1 .Location in patent: Page/Page column 65.

2
[ 406482-22-2 ]
[ 1104635-14-4 ]
[ 1104635-16-6 ]

Yield	Reaction Conditions	Operation in experiment
		Step 3 ) n-BuLi (1.1 eq) was added to a solution of 40 mg l-Bromo-2,3-difluoro-4-methoxy-benzene in 5 ml dry ether at -78C under N2. 440 mg (1.61 mmol) 2-Bromo-3-isobutoxy-4,5,6,6a-tetrahydro-3aH- pentalen-1-one dissolved in 5 ml dry ether and cooled to -78C was added drop wise. The mixture was stirred under N2 and the temperature was slowly raised overnight. The reaction was quenched with 10 ml water followed by 10 ml HCl (2N). The aqueous mixture was extracted with ether 3x and the combined organic layers were washed with brine and dried over Na2SO4. Concentration followed by purification on silica using a ether/n-heptane (1 :9-2:8) gradient afforded 390 mg 2-Bromo-3-(2,3-difluoro-4-methoxy- phenyl)-4,5,6,6a-tetrahydro-3aH-pentalen-l-one as a clear oil which solidified after a while.

References: [1]Patent: WO2009/12954,2009,A1 .Location in patent: Page/Page column 65.

3
[ 144292-32-0 ]
[ 77-78-1 ]
[ 406482-22-2 ]

References: [1]Synlett,2011,p. 1273 - 1276.

4
[ 406482-22-2 ]
[ 1053236-86-4 ]
C₂₀H₂₈F₂O₂ [ No CAS ]

References: [1]Synlett,2011,p. 1273 - 1276.

5
[ 406482-22-2 ]
[ 1053236-86-4 ]
C₂₀H₂₆F₂O [ No CAS ]

References: [1]Synlett,2011,p. 1273 - 1276.

6
[ 121-43-7 ]
[ 406482-22-2 ]
(2,3-difluoro-4-methoxyphenyl)boronic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		A 1.6M solution of tert-butyl lithium in pentane (23.4 mL, 37.5 mmol, 2.2 equ) was added dropwise under nitrogen at -78C to a solution of l-bromo-2,3-difluoro-4-methoxybenzene (3.8 g, 17.0 mmol) in anhydrous tetrahydrofuran (40 mL) and the resulting yellow/red solution was stirred for 45 min. at -78 C before the addition of trimethyl borate (5.69 mmol, 51.0 mmol, 3 equ). The resulting pale yellow solution was stirred for 16 h and the reaction was quenched with 3N HC1. The mixture was stirred for 2 h and water was added. The product was extracted with diethyl ether and the combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The product was triturated with hexane, filtered and dried under suction to give the title compound as an off-white solid (2.53 g, 79% yield).<¾ (DMSO-d6): 8.16 (2H, s (br)), 7.31-7.36 (1H, ddd, J=8.6, 6.6, 2.3), 6.96-7.00 (1H, ddd, J=8.6, 7.3, 1.5), 3.87 (3H, s).Note: The estimated purity of the product as determined by NMR was 80% and the product was used without further purification in the next step.

References: [1]Patent: WO2012/175991,2012,A1 .Location in patent: Page/Page column 78-79.

7
[ 144292-32-0 ]
[ 74-88-4 ]
[ 406482-22-2 ]

Yield	Reaction Conditions	Operation in experiment
100%	With potassium carbonate; In N,N-dimethyl-formamide; for 72h;	Methyl iodide (1.56 mL, 25.1 mmol, 1.5 equ) was added dropwise to a suspension of 4-bromo- 2,3-difluorophenol (3.5 g, 16.7 mmol) and potassium carbonate (2.77 g, 20.0 mmol, 1.2 equ) in N,N-dimethylformamide (30 mL) and the mixture was stirred for 3 days. The precipitate was removed by filtration and the filtrate was concentrated to dryness in vacuo. Dichloromethane and water were added and the product was extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo to give l-bromo-2,3- difluoro-4-methoxybenzene as a white crystalline solid (3.8 g, quantitative).

References: [1]Patent: WO2012/175991,2012,A1 .Location in patent: Page/Page column 78.

8
[ 406482-22-2 ]
[ 1416857-97-0 ]